PRODUCT INFORMATION



y-Linolenic Acid methyl ester

Item No. 10006579

CAS Registry No.:	16326-32-2	
Formal Name:	6Z,9Z,12Z-octadecatrienoic acid,	
	methyl ester	
Synonyms:	Methyl GLA, Methyl γ-Linolenate,	
	SFE 19:3	
MF:	C ₁₉ H ₃₂ O ₂	
FW:	292.5	
Purity:	≥98%	
Supplied as:	A solution in ethanol	
Storage:	-20°C	
Stability:	≥2 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

 γ -Linolenic Acid methyl ester (methyl GLA) is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of methyl GLA in these solvents is at least 100 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of methyl GLA is needed, it can be prepared by evaporating the ethanol and directly dissolving the neat oil in aqueous buffers. The solubility of methyl GLA in PBS (pH 7.2) is at least 0.15 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Polyunsaturated fatty acids (PUFAs) are essential nutrients that show distinct deficiency syndromes when not present in adequate amounts in the diet.^{1,2} Methyl GLA is an esterified version of the free acid which is less water soluble but more ammenable for the formulation of GLA-containing diets and dietary supplements. GLA is an ω -6 fatty acid which can be elongated to arachidonic acid for endogenous eicosanoid synthesis. It is a weak leukotriene B_4 (LTB₄) receptor antagonist, inhibiting [³H]-LTB₄ binding to porcine neutrophil membranes with a K of 1 μ M³ GLA produces 53% inhibition at a 1 mg/kg dose in an *in vivo* model of LTB₄-induced bronchoconstriction.³

References

- 1. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr. 54, 438-463 (1991).
- 2. Holman, R.T. Control of polyunsaturated acids in tissue lipids. J. Am. Coll. Cardiol. 5, 183-211 (1986).
- 3. Yagaloff, K.A., Franco, L., Simko, B., et al. Essential fatty acids are antagonists of the leukotriene B₄ receptor. Prostaglandins Leukot. Essent. Fatty Acids 52, 293-297 (1995).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/13/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM